MedTrace Logo

Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).

NCT01734265 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2014-01-29

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety and tolerance of a rush build up administration of Depigoid forte pollen and the first maintenance dose administered 4 weeks later.

Conditions

  • Allergy
  • Rhinitis
  • Rhinoconjunctivitis
  • Seasonal Asthma

Interventions

DRUG

Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)

DRUG

Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)

Sponsors & Collaborators

  • Laboratorios Leti, S.L.

    lead INDUSTRY

Principal Investigators

  • Pedro Guardia, Dr · H. Virgen Macarena

  • Joaquín Quiralte, Dr · H. Virgen del Rocío

  • Luis Angel Navarro, Dr · H. Luis Alcañiz

  • Santiago Nevot, Dr · H. Manresa

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-03-31
Completion
2013-04-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01734265 on ClinicalTrials.gov